Tesamorelin Peptide
Tesamorelin 5 mg contains Tesamorelin, a synthetic stabilized analogue of human growth hormone-releasing hormone (GHRH) with a trans-3-hexenoic acid modification at the N-terminus. This structural modification blocks dipeptidyl peptidase IV (DPP-IV) cleavage, extending the peptide's plasma half-life compared to endogenous GHRH, which is rapidly degraded.
Tesamorelin is FDA-approved for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy under the brand name EGRIFTA. Clinical trials have demonstrated significant reductions in visceral adipose tissue (VAT), with a pooled analysis showing a mean decrease of 24 cm² versus an increase of 2 cm² in placebo-treated patients over 26 weeks. In non-medical bodybuilding contexts, Tesamorelin is commonly referenced for visceral fat reduction and body recomposition research, though such use falls outside approved indications.
Tesamorelin stimulates endogenous growth hormone secretion by binding to GHRH receptors on pituitary somatotroph cells, preserving the body's natural pulsatile GH release and IGF-1 feedback regulation. This mechanism distinguishes it from exogenous growth hormone administration and from ghrelin receptor agonists such as Ipamorelin.
Key Benefits of Tesamorelin 5 mg
- FDA-approved GHRH analogue for visceral fat reduction in HIV lipodystrophy
- Stabilized structure with extended half-life compared to endogenous GHRH
- Stimulates endogenous GH secretion via GHRH receptor binding
- Preserves natural IGF-1 feedback regulation of growth hormone release
- Lyophilized powder format for extended storage stability
GHRH Receptor Agonist
Tesamorelin binds and activates the GHRH receptor on pituitary somatotroph cells with affinity comparable to endogenous GHRH. This binding stimulates the synthesis and pulsatile release of endogenous growth hormone, which then exerts lipolytic and anabolic effects through GH receptors on target tissues including adipocytes and hepatocytes.
Unlike growth hormone secretagogues that act via ghrelin receptors (such as Ipamorelin or GHRP-2), Tesamorelin acts specifically through the GHRH receptor pathway. Its mechanism preserves the body's natural feedback regulation, allowing IGF-1 levels to modulate GH release rather than producing supraphysiologic hormone exposure.
Clinical studies have demonstrated that Tesamorelin reduces visceral adipose tissue, trunk fat, and hepatic fat while increasing lean body mass, without significant reductions in subcutaneous adipose tissue or BMI. Effects on fat quality, measured by CT density, have also been documented independent of fat quantity changes.
Defining Characteristic
Stabilized GHRH Analogue with Extended Half-Life
Tesamorelin's trans-3-hexenoic acid modification blocks DPP-IV cleavage, extending its half-life and making peripherally administered GHRH therapy pharmacologically viable. This distinguishes it from Sermorelin, which has a shorter half-life and less extensive clinical validation.
Tesamorelin 5 mg vs Other Peptide Hubs Preparations
Peptide Hubs offers Tesamorelin in a 5 mg lyophilized powder format. Related GHRH analogue research peptides include Sermorelin 5 mg, another GHRH(1-29) analogue with a shorter half-life and less extensive clinical data. For research involving ghrelin receptor pathways, Ipamorelin 5 mg represents an alternative mechanism of GH stimulation.
A combination product containing Tesamorelin and Ipamorelin is available as Tesamorelin/Ipamorelin 10 mg, combining GHRH receptor and ghrelin receptor mechanisms for research applications.
Typical Dosage Ranges
In the FDA-approved clinical context for HIV-associated lipodystrophy, Tesamorelin is administered at 1.4 mg or 1.28 mg subcutaneously once daily depending on the formulation. In non-medical bodybuilding research contexts, Tesamorelin is commonly referenced at 1 mg to 2 mg per day, typically administered subcutaneously in the evening or before bed to mimic the body's natural nocturnal GH release pattern.
| Use Case | Common Reference Range | Injection Frequency |
|---|
| FDA-approved (HIV lipodystrophy) | 1.28–1.4 mg / day | Once daily subcutaneous |
| Bodybuilding research (non-medical) | 1–2 mg / day | Once daily, typically evening |
| Research protocols | Protocol-dependent | Per experimental design |
Note: Clinical trials used 2 mg doses of the older 1 mg/vial formulation, while current FDA-approved dosing for EGRIFTA SV is 1.4 mg once daily from the 2 mg/vial formulation.
Stacking & Cycle Considerations
In non-medical research contexts, Tesamorelin is sometimes referenced in combination with ghrelin receptor agonists such as Ipamorelin 5 mg or CJC-1295 No DAC 5 mg, as these act via complementary pathways to stimulate GH release. A pre-formulated blend is also available as Tesamorelin/Ipamorelin 10 mg.
Cycle lengths referenced in clinical research contexts range from 26 to 52 weeks. Non-medical protocols commonly reference shorter cycles of 8 to 16 weeks.
Managing Side Effects
Reported adverse effects from clinical trials include injection site reactions (erythema, pruritus, pain, irritation, bruising), arthralgia, myalgia, paresthesia, and peripheral edema. Mild fluid retention can occur early in treatment. The FDA labeling notes that Tesamorelin can cause increases in glucose intolerance and recommends periodic blood sugar monitoring.
Post-Cycle Therapy
Post-cycle therapy is not applicable to Tesamorelin, as the peptide does not suppress endogenous testosterone production or alter the hypothalamic-pituitary-gonadal axis. Tesamorelin acts on the GH-IGF-1 axis through GHRH receptor stimulation without direct androgenic effects.
Important
Individual Response Varies
Research peptide protocols should be based on published study designs and appropriate institutional oversight. The information above is for educational reference and does not constitute medical advice or a recommendation for use.
Important Safety Information
Tesamorelin stimulates endogenous growth hormone secretion, which increases IGF-1 levels. Elevated IGF-1 is associated with theoretical risks including promotion of pre-existing malignancies. Active malignancy is a contraindication to Tesamorelin use.
Tesamorelin is not recommended for use in children and is not known to be safe or effective in pediatric populations. The FDA labeling states that the impact and safety of EGRIFTA on cardiovascular health has not been studied.
Important
Non-Medical Use
Tesamorelin is a prescription medication approved for HIV-associated lipodystrophy. Non-medical use of research peptides falls outside approved indications and carries unknown risks. Purchasing or using injectable Tesamorelin without a prescription may be illegal depending on jurisdiction.
Potential Adverse Effects
Common adverse reactions reported in clinical trials include injection site reactions (erythema, pruritus, pain, irritation, bruising), arthralgia, myalgia, paresthesia, peripheral edema, and pain in legs and arms. Serious allergic reactions including rash, facial or throat swelling, and shortness of breath have been reported.
Tesamorelin can cause fluid retention and increases in glucose intolerance. Blood sugar should be monitored periodically during use. A meta-analysis found no significant perturbation of glucose parameters in clinical trial populations.
Conditions Requiring Medical Evaluation
Tesamorelin is contraindicated in patients with pituitary gland tumors, pituitary surgery, or other pituitary problems; active cancer (newly diagnosed or recurrent) or receiving cancer treatment; and known hypersensitivity to Tesamorelin. It is also not recommended for pregnant or breastfeeding individuals.
Patients with diabetes, kidney or liver problems, or a history of cancer should discuss these conditions with a healthcare professional before Tesamorelin use.
Monitoring During Therapy
Clinical use of Tesamorelin typically involves periodic monitoring of blood sugar and IGF-1 levels. Injection sites should be rotated to reduce the risk of injection site reactions. The FDA labeling advises patients to never share syringes or needles with another person, even if the needle is changed.
Product Care
Storage & Handling
Keep the vial securely stored and protected from conditions that could compromise the product. Inspect the vial before use and do not use a product that appears damaged or compromised.
Keep all medications and injectable products out of the reach of children. Follow the storage instructions provided with the product packaging.
Further Safety Information
USA Domestic 3–5 business days
International 10–15 business days
Order Processing 24–48 business hours
Tracking Provided after dispatch
Direct Supply
Discreet Delivery & Original Packaging
The outer shipping package remains discreet, with privacy-focused handling. Products are supplied through the official Peptide Hubs distribution chain.
What to Expect
- Orders are processed after payment confirmation
- USA Domestic shipping is typically faster when local stock is selected
- International orders include tracking, though update frequency may vary by destination
- Multiple warehouses may result in separate shipments when applicable
Authenticity Verification
To verify your Tesamorelin 5 mg product, use the security code on the vial label and cross-check it on the Peptide Hubs official site. Original packaging helps reinforce product legitimacy.
For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.
Recommended Conditions
Store the lyophilized powder refrigerated at 2–8°C and protected from light. Keep the vial in its original packaging until use.
After reconstitution, the FDA labeling for EGRIFTA indicates that the reconstituted solution should be used immediately and not frozen or refrigerated. For research applications, follow the reconstitution instructions provided with the product.
Reconstituted Tesamorelin solution should be clear and colorless. Cloudiness or visible particulates indicate degradation and the vial should be discarded.
Quick Reference
Do & Don't
- Do store lyophilized powder refrigerated at 2–8°C
- Do protect from light and moisture
- Do use reconstituted solution promptly
- Don't freeze reconstituted solution
- Don't expose to excessive heat
- Don't use if solution appears cloudy or discolored
What is Tesamorelin 5 mg used for?
Tesamorelin 5 mg is a research peptide supplied as lyophilized powder. Tesamorelin is FDA-approved for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. In non-medical research contexts, it is studied for visceral fat reduction and body composition applications.
How often should Tesamorelin 5 mg be injected?
In the FDA-approved clinical context, Tesamorelin is administered subcutaneously once daily at 1.28–1.4 mg depending on the formulation. In non-medical research contexts, the same once-daily frequency is commonly referenced.
Does Tesamorelin 5 mg require PCT?
No. Post-cycle therapy is not applicable to Tesamorelin, as the peptide does not suppress endogenous testosterone production or alter the hypothalamic-pituitary-gonadal axis. Tesamorelin acts on the GH-IGF-1 axis through GHRH receptor stimulation without direct androgenic effects.
What does Tesamorelin do?
Tesamorelin is a stabilized GHRH analogue that binds to GHRH receptors on pituitary somatotroph cells, stimulating endogenous growth hormone synthesis and pulsatile secretion. This mechanism preserves the body's natural IGF-1 feedback regulation, unlike exogenous growth hormone administration.
How long does Tesamorelin take to work?
In clinical trials, visceral fat changes with Tesamorelin typically appear by 12 weeks, with continued improvement observed at 26 weeks. Peak plasma concentration is reached approximately 0.15 hours after subcutaneous administration.
Is Tesamorelin approved by the FDA?
Yes. Tesamorelin received initial FDA approval in 2010 under the brand name EGRIFTA for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. It is not indicated for weight loss management or general obesity treatment.
What is the difference between Tesamorelin and Sermorelin?
Tesamorelin and Sermorelin are both GHRH analogues, but they differ in half-life and clinical validation. Tesamorelin is stabilized with a trans-3-hexenoic acid modification for longer half-life and has stronger clinical data, particularly for visceral fat reduction. Sermorelin 5 mg is a shorter-acting GHRH(1-29) analogue available from Peptide Hubs.
What is the difference between Tesamorelin and Ipamorelin?
Tesamorelin and Ipamorelin act through different mechanisms. Tesamorelin is a GHRH receptor agonist, while Ipamorelin is a selective ghrelin receptor agonist. Both stimulate GH release but via complementary pathways. Ipamorelin 5 mg is available from Peptide Hubs for research use.
Is 5 mg a lot of Tesamorelin?
A 5 mg vial of Tesamorelin is a research-scale quantity. At FDA-approved daily doses of 1.28–1.4 mg, a 5 mg vial provides approximately 3–4 days of material depending on the protocol.
What strength is Tesamorelin 5 mg?
Tesamorelin 5 mg by Peptide Hubs is labeled at 5 mg per vial. The product is supplied as lyophilized powder in a 2 mL vial.
How should Tesamorelin 5 mg be reconstituted?
Lyophilized peptides are typically reconstituted with bacteriostatic water or sterile saline. Bacteriostatic Water is commonly used for peptide reconstitution to maintain sterility over multiple draws. For a 5 mg vial, adding 1 mL of diluent yields a concentration of 5 mg per mL.
What should I know about Tesamorelin storage?
Lyophilized Tesamorelin should be stored refrigerated at 2–8°C and protected from light. Once reconstituted, the FDA labeling for EGRIFTA indicates that the solution should be used promptly and not frozen or refrigerated.
No reviews found
Please log in to write Tesamorelin 5 mg review.
